Established in Hyderabad in 1978 and now spread its operations in 60 countries serving mainly in United States, Europe. It is one of the fastest growing generic injectables-focused companies. They are presently in sterile injectables, oncology and ophthalmics, and focus on complex injectables, NCE-1s, First-to-File products and 505(b)(2) filings.
They have seven manufacturing facilities in India.They sell their products primarily under a business to business (“B2B”) model.
Global Pharmaceutical market grew at a CAGR of approximately 5.8% from 2014 to reach US$1,096 billion in 2019. The market is estimated to reach US$1,359 billion by 2024. North America is expected to contribute approximately 47% of the overall market by value in 2024. India and China are expected to contribute approximately 2% and 9%, respectively, of the market by value, with India expected to grow at a faster rate than china.
Promoters of the company
Fosun Singapore and Shanghai Fosun Pharma are the Promoters of the Company.
- Diversified B2B-led model across markets, complemented by a targeted B2C model in India
- Extensive portfolio of complex products supported by internal R&D and regulatory capabilities.
- Track record of growth and profitability from a diversified revenue base with healthy cash flows.
Yiu Kwan Stanley Lau: Chairman and Independent Director.
Srin ivas Sadu: MD and CEO.
Objects of the Issue
1. Funding incremental working capital requirements of the Company;
2. Funding capital expenditure requirements of the Company; and
3. General corporate purposes.
The following table sets forth their revenue from operations based on the customer location as a percentage
of the total revenue from operations for the years specified.
|Rest of the world||5.10%||11.59%||8.80%|
|IPO date||Nov 9- Nov 11,(2020)|
|Issue size||6,480 Cr( 43,196,968 Eq shares)|
|Listing price band||1490 -1500 per equity share|
|Face value||1 Rs|
|1 Lot size||shares|
|Minimum quote||15,000 Rs|
|Maximum quote||1,95,000 Rs|
|Offer opens on||Nov 9, 2020|
|Offer closes on||Nov 11, 2020|
|Credit of shares in demat account||Nov 19,2020|
|Listing date||Nov 20, 2020|
To invest in this IPO you need a Demat and Trading account and UPSTOX which is entrusted by Ratan Tata is one of the leading providers of Demat and Trading in a single account. Opening of demat account doesn’t take more than 5 min of your time. Click the link to open free demat account with Upstox. If you have any doubt about how to open an account please feel free to whatsapp me (8919251188).